Madrigal Pharmaceuticals Enters Material Definitive Agreement
Ticker: MDGL · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1157601
Sentiment: neutral
Topics: material-definitive-agreement, partnership
TL;DR
Madrigal Pharma just signed a big deal, details TBD.
AI Summary
Madrigal Pharmaceuticals, Inc. announced on March 18, 2024, that it entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement or any associated dollar amounts. The company is incorporated in Delaware and its principal executive office is located in West Conshohocken, Pennsylvania.
Why It Matters
This filing indicates a significant new contract or partnership for Madrigal Pharmaceuticals, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its terms and potential impact.
Key Players & Entities
- Madrigal Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- West Conshohocken, Pennsylvania (location) — Principal executive office
- March 18, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Madrigal Pharmaceuticals?
The filing does not specify the nature of the Material Definitive Agreement.
When did Madrigal Pharmaceuticals enter into this Material Definitive Agreement?
Madrigal Pharmaceuticals entered into the Material Definitive Agreement on March 18, 2024.
Are there any financial terms disclosed for this agreement?
No, the filing does not disclose any specific dollar amounts or financial terms related to the agreement.
Where is Madrigal Pharmaceuticals, Inc. headquartered?
Madrigal Pharmaceuticals, Inc.'s principal executive office is located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428.
What is the SIC code for Madrigal Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Madrigal Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,478 words · 6 min read · ~5 pages · Grade level 11.6 · Accepted 2024-03-20 16:11:40
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MDGL The NASDAQ
- $260.00 — public offering price for the Shares is $260.00 per share, less underwriting discounts
- $259.9999 — ng price for the Pre-Funded Warrants is $259.9999 per Pre-Funded Warrant, which represent
- $574.0 m — e by the Company, will be approximately $574.0 million, excluding any exercise of the Un
Filing Documents
- d774533d8k.htm (8-K) — 35KB
- d774533dex11.htm (EX-1.1) — 168KB
- d774533dex51.htm (EX-5.1) — 12KB
- g774533g0320085521236.jpg (GRAPHIC) — 2KB
- 0001193125-24-072706.txt ( ) — 395KB
- mdgl-20240318.xsd (EX-101.SCH) — 3KB
- mdgl-20240318_lab.xml (EX-101.LAB) — 18KB
- mdgl-20240318_pre.xml (EX-101.PRE) — 11KB
- d774533d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) The following exhibits are filed as part of this report: Exhibit Number Description 1.1 Underwriting Agreement, dated March 18, 2024. 4.1 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on October 2, 2023). 5.1 Opinion of Hogan Lovells US LLP. 23.1 Consent of Hogan Lovells US LLP (included in the opinion filed as Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Madrigal Pharmaceuticals, Inc. (the Registrant) Date: March 20, 2024 By: /s/ Mardi C. Dier Mardi C. Dier Senior Vice President and Chief Financial Officer